The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...

SheKnows: How do you manage your vitiligo? Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I first noticed some ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Stifel's updated model for Incyte includes incremental additions and revisions, taking into account lower projections for Opzelura and povorcitinib, while maintaining the Hold rating on the ...

Adjusted EPS was $1.43, missing the $1.56 estimate. Jakafi revenue rose 11% to $773.1M, while Opzelura sales jumped 48% to $161.6M. Minjuvi/Monjuvi revenue surged 265% to $32.81M. Our government ...

The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline, with four product launches in 2025 and potential $1B ...

Jakafi Net Sales: $2.8 billion in 2024, up 8% year-over-year. Opzelura Revenue: $508 million in 2024, a 50% increase from 2023. Q4 2024 Revenue: $1.2 billion, up 16% from Q4 2023. Cash Position ...